Hydralazine in the management of symptomatic sinus bradycardia.

European journal of cardiology Pub Date : 1981-01-01
A T Weiss, J L Rod, M S Gotsman, B S Lewis
{"title":"Hydralazine in the management of symptomatic sinus bradycardia.","authors":"A T Weiss,&nbsp;J L Rod,&nbsp;M S Gotsman,&nbsp;B S Lewis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Hydralazine (Apresoline) was used to increase heart rate in 21 patients (14 hypertensive and 7 normotensive) suffering from symptomatic sinus bradycardia (SSB). Patients were assessed clinically and by 24-h ECG analysis before and after tailored increasing doses of the drug. Heart rates measured were resting (basal) rate, minimum rate during sleep, maximal rate during the day, and mean rate during the 24-h period (from hourly strips). The longest sinus pause or period of sinus arrest (when present) was also measured. Hydralazine ameliorated symptoms and produced a 20% or greater increase in heart rate in just under two-thirds of the hypertensive and half of the normotensive patients. Blood pressure decreased slightly in hypertensive but not in normotensive patients, and there were no important side-effects. Hydralazine appears to be a useful and effective drug to increase heart rate in patients with SSB.</p>","PeriodicalId":72971,"journal":{"name":"European journal of cardiology","volume":"12 5","pages":"261-70"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of cardiology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hydralazine (Apresoline) was used to increase heart rate in 21 patients (14 hypertensive and 7 normotensive) suffering from symptomatic sinus bradycardia (SSB). Patients were assessed clinically and by 24-h ECG analysis before and after tailored increasing doses of the drug. Heart rates measured were resting (basal) rate, minimum rate during sleep, maximal rate during the day, and mean rate during the 24-h period (from hourly strips). The longest sinus pause or period of sinus arrest (when present) was also measured. Hydralazine ameliorated symptoms and produced a 20% or greater increase in heart rate in just under two-thirds of the hypertensive and half of the normotensive patients. Blood pressure decreased slightly in hypertensive but not in normotensive patients, and there were no important side-effects. Hydralazine appears to be a useful and effective drug to increase heart rate in patients with SSB.

肼嗪治疗症状性窦性心动过缓。
对21例伴有症状性窦性心动过缓(SSB)的患者(高血压14例,血压正常7例)应用海氮嗪(阿替瑞林)提高心率。在量身定制的增加药物剂量之前和之后,通过临床和24小时ECG分析对患者进行评估。测量的心率为静息(基础)心率、睡眠时的最小心率、白天的最大心率和24小时内的平均心率(取自每小时的心率条)。最长的窦停或窦停期间(当存在时)也被测量。在近三分之二的高血压患者和一半的正常患者中,海氮嗪改善了症状,并使心率增加了20%或更多。高血压患者的血压略有下降,而正常患者则没有,并且没有重要的副作用。海氮嗪似乎是一种有用和有效的药物,以提高心率的患者SSB。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信